Literature DB >> 10094469

Transcriptional activation of the human S100A2 promoter by wild-type p53.

M Tan1, C W Heizmann, K Guan, B W Schafer, Y Sun.   

Abstract

S100A2, a calcium binding protein of the EF-hand family, was recently identified to be inducible by etoposide, a p53 activator. A potential p53 binding site was identified in the promoter of the S100A2 gene, which binds to purified p53 as well as p53 in nuclear extract activated by etoposide. Transactivation assays using the promoter driven luciferase reporters revealed that the S100A2 promoter was transcriptionally activated by wild-type p53, but not by p53 mutants, in a dose-dependent as well as a p53 binding site-dependent manner. The p53-induced transactivation of the S100A2 promoter was enhanced by etoposide and blocked by a dominant negative p53 mutant. Furthermore, endogenous S100A2 mRNA expression is induced by etoposide in p53 positive, but not in p53 negative cells. Thus, p53 appears to positively regulate S100A2 expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094469     DOI: 10.1016/s0014-5793(99)00135-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  16 in total

1.  PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway.

Authors:  M Tan; Y Wang; K Guan; Y Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Role for BRG1 in cell cycle control and tumor suppression.

Authors:  Kristin B Hendricks; Frances Shanahan; Emma Lees
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

3.  Differential recognition of response elements determines target gene specificity for p53 and p63.

Authors:  Motonobu Osada; Hannah Lui Park; Yuichi Nagakawa; Keishi Yamashita; Alexey Fomenkov; Myoung Sook Kim; Guojun Wu; Shuji Nomoto; Barry Trink; David Sidransky
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

4.  Concerted regulation of wild-type p53 nuclear accumulation and activation by S100B and calcium-dependent protein kinase C.

Authors:  C Scotto; C Delphin; J C Deloulme; J Baudier
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

5.  Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.

Authors:  Rebekka K Schneider; Monica Schenone; Monica Ventura Ferreira; Rafael Kramann; Cailin E Joyce; Christina Hartigan; Fabian Beier; Tim H Brümmendorf; Ulrich Germing; Uwe Platzbecker; Guntram Büsche; Ruth Knüchel; Michelle C Chen; Christopher S Waters; Edwin Chen; Lisa P Chu; Carl D Novina; R Coleman Lindsley; Steven A Carr; Benjamin L Ebert
Journal:  Nat Med       Date:  2016-02-15       Impact factor: 53.440

6.  Significance of S100A2 and S100A4 Expression in the Progression of Prostate Adenocarcinoma.

Authors:  Yong-Wook Kwon; In Ho Chang; Kyung Do Kim; Young Sun Kim; Soon-Chul Myung; Mi-Kyung Kim; Tae-Hyoung Kim
Journal:  Korean J Urol       Date:  2010-07-20

7.  A gene signature-based approach identifies mTOR as a regulator of p73.

Authors:  Jennifer M Rosenbluth; Deborah J Mays; Maria F Pino; Luo Jia Tang; Jennifer A Pietenpol
Journal:  Mol Cell Biol       Date:  2008-08-04       Impact factor: 4.272

Review 8.  S100 protein family in human cancer.

Authors:  Hongyan Chen; Chengshan Xu; Qing'e Jin; Zhihua Liu
Journal:  Am J Cancer Res       Date:  2014-03-01       Impact factor: 6.166

9.  Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas.

Authors:  Carlos S Moreno; Lilya Matyunina; Erin B Dickerson; Nina Schubert; Nathan J Bowen; Sanjay Logani; Benedict B Benigno; John F McDonald
Journal:  PLoS One       Date:  2007-05-16       Impact factor: 3.240

10.  Transcriptional activation of the tumor suppressor and differentiation gene S100A2 by a novel p63-binding site.

Authors:  Ralf D Kirschner; Katja Sänger; Gerd A Müller; Kurt Engeland
Journal:  Nucleic Acids Res       Date:  2008-04-03       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.